Skip to research
Margin Monkey THEMARGINMONKEY Start my free trialTry free

Insulet (PODD) stock in plain English

Free brief · no signupStart here
PODDPublished Nov 12, 2026
Insulet Corp
Healthcare · Medical Devices
Produces wearable, tubeless insulin delivery devices and digital management software for people with diabetes.
Assets:
Over 600,000 active usersworldwide customer base using automated insulin delivery systems
Acton manufacturing facilityprimary automated production plant in Massachusetts
Omnipod 5 delivery systemflagship automated tubeless insulin delivery product line
Locked assetIn the full report
Rated Nov 19, 2026

Every company we rate gets Strong Buy, Buy, Buy with Caution, Hold or Sell. Members see the rating for this company and the five scores behind it.

77
OPS ScoreOperating finances
Latest quote
-1.96%$137.23
$9.52B
23.5×
$3.18B

Change shown by the quote provider. Data may be delayed.

Financial statements, in plain wordsSales, profit, debt and cash, year by year
Published Nov 12, 2026Quotes updated Nov 20, 04:05 UTCOPS Score, TMM Score and the rating are research summaries, not advice or forecasts.
That was PODD. The desk has 1,900+ more companies.Each one comes with its scores, its flags and the sources behind them.
7 days free · No card

What does Insulet (PODD) do?

Insulet Corp (PODD) is a U.S.-listed company in Healthcare (Medical Devices). What it does: Produces wearable, tubeless insulin delivery devices and digital management software for people with diabetes. Manufactures tubeless, wearable insulin pods that eliminate external catheters for continuous diabetes management. It is worth $9.52B on the market and sold $3.18B over the last year.

Market cap
$9.52B
P/E ratio
23.5×
Annual sales
$3.18B
Sector
Healthcare
Industry
Medical Devices
Brief updated
Nov 12, 2026

Brands and businesses behind PODD

  • Omnipod: Sells wearable disposable insulin pods and controllers that generate revenue through ongoing pharmacy prescription refills.

PODD’s flags, in plain English

Each flag is a number from Insulet’s reports to the SEC or from market data, with the reason it matters. This brief was updated on Nov 12, 2026.

Wide Gross Margin

Gross margin of 72.9% after the cost of making its products. There is a large gap between what its products cost to make and what they sell for, and that gap pays for everything else.

Earns Its Keep

Earns 28.9% a year on shareholders' money. The company earns a healthy return on the money its shareholders have put in.

Still Climbing

Sales up 24.5% a year over 5 years. Sales are higher than a year ago. Growth does not guarantee profit, so look at the margins too.

Worth a Look

Competing medical technology companies sell automated insulin delivery pumps and integrated sensors that create pricing and market share pressure. Something here could change the picture, so it is worth reading next to the good news.

2 more green flags open with the free trial. Try it free for 7 days.

Questions about PODD

How big is Insulet?

Insulet’s market cap is $9.52B: what all of its shares are worth together at today’s price. Its annual sales (revenue) are $3.18B: what customers paid the company over the last year, before any costs.

What is PODD’s P/E ratio?

PODD’s P/E ratio is 23.5×. Investors pay about 23.5 dollars for each dollar of the company’s yearly profit. A low number can mean a bargain or a problem, so read it next to the flags.

What could go wrong with PODD?

The first risk note on the card is Worth a Look, explained above. A flag reads what the company reported. It does not predict the price.

Where do these numbers come from?

From Insulet’s own reports to the SEC (annual and quarterly) and from market data. Every company runs through the same scoring formula, and a reviewer spot-checks cards against the source data. PODD’s filings on SEC.gov. The Margin Monkey is research, not advice.

Your first 7 days are free.Search all 1,900+ companies and open every card. Members also get the ratings, Picks and the TMM Score.
7 days free · No card